Authors:
CVITKOVIC E
MARTY M
WASSERMAN E
CUVIER C
GOLDWASSER F
MISSET JL
Citation: E. Cvitkovic et al., IRINOTECAN-RELATED CHOLINERGIC SYNDROME INDUCED BY COADMINISTRATION OF OXALIPLATIN, Journal of the National Cancer Institute, 90(13), 1998, pp. 1016-1017
Authors:
GOLDWASSER F
GROSS M
CHOUAKI N
BUTHAUD X
RIOFRIO M
TIGAUD JM
RISSE ML
MISSET JL
CVITKOVIC E
Citation: F. Goldwasser et al., OXALIPLATINE (L-OHP) CPT11 COMBINATION EVERY 2 WEEKS - RESULTS OF AN ONGOING PHASE-I STUDY IN ADVANCED DIGESTIVE MALIGNANCIES/, Annals of oncology, 9, 1998, pp. 234-234
Authors:
RIOFRIO M
TAAMMA A
MCKRANTER B
GOLDWASSER F
JIMENO J
JASMIN C
MISSET JL
CVITKOVIC E
Citation: M. Riofrio et al., ECTEINASCIDIN-743 (ET-743) 24 HOURS CONTINUOUS-INFUSION (CI) - CLINICAL AND PHARMACOKINETIC PHASE-I STUDY PROGRESSIVE REPORT, Annals of oncology, 9, 1998, pp. 639-639
Authors:
GROSS M
LOKIEC F
LEMOINE A
CASTAING D
SAMUEL D
LEVI F
MISSET JL
GOLDWASSER F
Citation: M. Gross et al., INTERACTION BETWEEN TOPOTECAN AND CYCLOSPORINE - CLINICAL-RESULTS ANDPHARMACOKINETICS OVER 3 COURSES, Annals of oncology, 9, 1998, pp. 668-668
Authors:
BUTHAUD X
GOLDWASSER F
GROSS M
BLEUZEN P
CVITKOVIC E
JASMIN C
MISSET JL
Citation: X. Buthaud et al., TOPOTECAN-INDUCED SEVERE THROMBOCYTOPENIA - EVIDENCE FOR A REGRESSIVEINCIDENCE PATTERN ON SUCCESSIVE TREATMENT CYCLES (CY), Annals of oncology, 9, 1998, pp. 258-258
Authors:
GROSS M
CVITKOVIC E
WASSERMAN E
GOLDWASSER F
CHOUAKI N
RIOFRIO M
OULDKACI M
TIGAUD JM
MIGNARD D
MISSET JL
Citation: M. Gross et al., CPT-11 OXALIPLATIN (L-OHP) COMBINATION - COMPARISON OF THE TOXICITY OF 2 SCHEDULES OF ADMINISTRATION/, Annals of oncology, 9, 1998, pp. 262-262
Authors:
CVITKOVIC E
MEKRANTER B
TAAMMA A
GOLDWASSER F
BEIJNEN JH
JIMENO J
RIOFRIO M
VEGA E
MISSET JL
HOP P
Citation: E. Cvitkovic et al., ECTEINASCIDIN-743 (ET-743) 24-HOUR CONTINUOUS INTRAVENOUS-INFUSION (CI) PHASE-I STUDY IN SOLID TUMORS (ST) PATIENTS, Annals of oncology, 9, 1998, pp. 456-456
Citation: Y. Takebayashi et al., PROTEIN-LINKED DNA BREAKS INDUCED BY ECTEINASCIDIN-743 IN HUMAN COLON-CARCINOMA CELLS, Annals of oncology, 9, 1998, pp. 531-531
Authors:
FAIVRE S
RAYMOND E
RIXE O
GOLDWASSER F
MANGOLD GL
VONHOFF DD
JUNIEWICZ P
CVITKOVIC E
Citation: S. Faivre et al., IN-VITRO AND IN-VIVO RATIONATE FOR OXALIPLATIN IN COMBINATION WITH OTHER ANTITUMOR AGENTS, Annals of oncology, 9, 1998, pp. 554-554
Authors:
WASSERMAN E
MYARA A
LOKIEC F
KACI MO
GOLDWASSER F
MAGHERINI E
CVITKOVIC E
MISSET JL
Citation: E. Wasserman et al., EVIDENCE FOR ENHANCED TOXICITY TO CPT-11 IN PATIENTS WITH GILBERTS-SYNDROME - 2 CASE-REPORTS, European journal of cancer, 33, 1997, pp. 1130-1130
Authors:
WASSERMAN E
MYARA A
LOKIEC F
GOLDWASSER F
TRIVIN F
MAHJOUBI M
MISSET JL
CVITKOVIC E
Citation: E. Wasserman et al., SEVERE CPT-11 TOXICITY IN PATIENTS WITH GILBERTS-SYNDROME - 2 CASE-REPORTS, Annals of oncology, 8(10), 1997, pp. 1049-1051
Citation: F. Goldwasser et al., DIFFERENTIAL GADD45, P21(C1P WAF1) MCL-1 AND TOPOISOMERASE-II GENE INDUCTION AND SECONDARY DNA FRAGMENTATION AFTER CAMPTOTHECIN-INDUCED DNA-DAMAGE IN 2 MUTANT P53 HUMAN COLON-CANCER CELL-LINES/, Oncology research, 8(7-8), 1996, pp. 317-323
Authors:
GOLDWASSER F
SHIMIZU T
JACKMAN J
HOKI Y
OCONNOR PM
KOHN KW
POMMIER Y
Citation: F. Goldwasser et al., CORRELATIONS BETWEEN S AND G(2) ARREST AND THE CYTOTOXICITY OF CAMPTOTHECIN IN HUMAN COLON-CARCINOMA CELLS, Cancer research, 56(19), 1996, pp. 4430-4437
Authors:
GOLDWASSER F
PICO JL
CERRINA J
FERNANDEZ H
PONS JC
COSSET JM
HAYAT M
Citation: F. Goldwasser et al., SUCCESSFUL CHEMOTHERAPY INCLUDING EPIRUBICIN IN A PREGNANT NON-HODGKINS-LYMPHOMA PATIENT, Leukemia & lymphoma, 20(1-2), 1995, pp. 173-176
Authors:
DUBREZ L
GOLDWASSER F
GENNE P
POMMIER Y
SOLARY E
Citation: L. Dubrez et al., THE ROLE OF CELL-CYCLE REGULATION AND APOPTOSIS TRIGGERING IN DETERMINING THE SENSITIVITY OF LEUKEMIC-CELLS TO TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITORS, Leukemia, 9(6), 1995, pp. 1013-1024
Authors:
EYMIN B
SOLARY E
CHEVILLARD S
DUBREZ L
GOLDWASSER F
DUCHAMP O
GENNE P
LETEURTRE F
POMMIER Y
Citation: B. Eymin et al., CELLULAR PHARMACOLOGY OF AZATOXINS (TOPOISOMERASE-II AND TUBULIN INHIBITORS) IN P-GLYCOPROTEIN-POSITIVE AND P-GLYCOPROTEIN-NEGATIVE CELL-LINES, International journal of cancer, 63(2), 1995, pp. 268-275
Authors:
GOLDWASSER F
BAE I
VALENTI M
TORRES K
POMMIER Y
Citation: F. Goldwasser et al., TOPOISOMERASE I-RELATED PARAMETERS AND CAMPTOTHECIN ACTIVITY IN THE COLON-CARCINOMA CELL-LINES FROM THE NATIONAL-CANCER-INSTITUTE ANTICANCER SCREEN, Cancer research, 55(10), 1995, pp. 2116-2121
Authors:
MARKOVITS J
JUNQUA S
GOLDWASSER F
VENUAT AM
LUCCIONI C
BEAUMATIN J
SAUCIER JM
BERNHEIM A
JACQUEMINSABLON A
Citation: J. Markovits et al., GENISTEIN RESISTANCE IN HUMAN LEUKEMIC CCRF-CEM CELLS - SELECTION OF A DIPLOID-CELL LINE WITH REDUCED DNA TOPOISOMERASE-II BETA-ISOFORM, Biochemical pharmacology, 50(2), 1995, pp. 177-186